Announcement


NeuroSearch A/S (NEUR) hereby releases the company’s financial calendar for
2012:

Financial calendar for 2011

28 February 2012 Annual Report 2011
25 April 2012 Annual General Meeting and interim report
for the first three months of 2012
30 August 2012 Interim report for the first six months of 2012
15 November 2011 Interim report for the first nine months of 2012

Patrik Dahlen
CEO

Contact person
René Schneider, EVP & CFO, telephone: +45 4460 8700 or +45 2911 2097


About NeuroSearch
NeuroSearch is a European-based biopharmaceutical company listed on NASDAQ OMX
Copenhagen A/S (NEUR) and specialising in central nervous system (CNS)
disorders. The vision is to develop NeuroSearch into a profitable specialty
pharmaceutical company. The strategy is primarily to complete the development
and subsequently to market Huntexil®, a unique drug in clinical Phase III for
the treatment of the motor symptoms of Huntington’s disease.
Among discontinuing activities, NeuroSearch also has a portfolio of assets for
outlicensing or divestment. This includes tesofensine which has shown promising
effect in the treatment of obesity, the Integrative Screening Process (ISP),
which is a proprietary systems biology approach, as well as a broad range of
ion channel technologies and patented compounds identified as ion channel
modulators.

Fonds.28-11 - Financial calendar for 2012 - uk.pdf